Soluble immune markers in the different phases of chronic hepatitis B virus infection

Steffen B. Wiegand\(^1,2\), Bastian Beggel\(^1\), Anika Wranke\(^1,2\), Elmira Aliabadi\(^1,2\), Jerzy Jaroszewicz\(^4\), Cheng-Jian Xu\(^1,8\), Yang Li\(^8,9\), Michael P. Manns\(^1\), Thomas Lengauer\(^2,5\), Heiner Wedemeyer\(^1,2,7\), Anke R. M. Kraft\(^1,2\), Christine S. Falk\(^2,6\) & Markus Cornberg\(^1,2,8,9\)

Chronic hepatitis B virus (HBV) infection may follow four different consecutive phases, which are defined by virology as well as biochemical markers and differ in terms of prognosis and need for antiviral treatment. Currently, host responses reflected by immune markers are not considered in this definition. We aimed to study soluble immune markers and their distribution in different phases of chronic HBV infection. In this cross-sectional retrospective study, we investigated a panel of 14 soluble immune markers (SIM) including CXCL10 in 333 patients with chronic HBV infection. In a small cohort of HBeAg positive patients we analyzed SIM before and after HBeAg seroconversion and compared seroconverters to patients with unknown outcome. Significant differences were documented in the levels of several SIM between the four phases of chronic HBV infection. The most pronounced difference among all investigated SIM was observed for CXCL10 concentrations with highest levels in patients with hepatitis. TGF-\(\beta\) and IL-17 revealed different levels between HBeAg negative patients. HBeAg positive patients with HBeAg seroconversion presented higher amounts of IL-12 before seroconversion compared to HBeAg positive patients with unknown follow up. SIM such as CXCL10 but also IL-12, TGF-\(\beta\) and IL-17 may be useful markers to further characterize the phase of chronic HBV infection.

Hepatitis B virus (HBV) is a global health burden with almost 250 million chronically infected people worldwide\(^1\). Chronic hepatitis B can lead to liver cirrhosis and hepatocellular carcinoma (HCC)\(^2\). The clinical courses differ remarkably from patient to patient and not all will develop cirrhosis and/or HCC. Therefore, early identification of patients with high risk of developing endpoints like cirrhosis and HCC is necessary, in order to define who is in need of close monitoring and/or antiviral treatment\(^2\).

Four phases of the natural course of chronic HBV infection are characterized, which are based on serological and biochemical parameters\(^l\). The different phases of chronic HBV infection are not necessarily sequential. HBeAg-positive patients are usually young patients with very high HBV DNA titers. A differentiation between HBeAg-positive HBV infection (EPI) (formally called immune tolerance phase) and the HBeAg-positive hepatitis phase (EPH) is based on the occurrence of inflammatory signs such as elevated transaminases or histology-proven inflammation and/or clinical hepatitis\(^2\). After seroconversion to anti-HBe, HBeAg-negative patients with low HBV DNA level (<2,000 IU/mL) and no signs of liver inflammation are part of the HBeAg-negative infection (ENI) (formerly inactive carrier). HBeAg-negative patients with HBV DNA > 2,000 IU/mL and elevated ALT or liver inflammation due to immune escape mutations in the pre-core or basal core promoter are defined as having HBeAg-negative hepatitis (ENH).

Current clinical practice guidelines recommend antiviral treatment in patients with active hepatitis phases (EPH and ENH) but not in patients with HBeAg-positive or negative infection (EPI or ENI)\(^2\). However, a
proportion of patients with HBeAg-negative chronic HBV infection and persistently normal ALT level have HBV DNA levels between 2,000 and 20,000 IU/ml. These patients are sometimes defined as grey-zone patients and some data suggest that these patients have no significant liver disease and no increased risk for disease progression1. However, long-term follow-up is important to define the phase. Since quantitative HBV DNA and ALT levels may fluctuate in the natural course, the discrimination of patients with or without hepatitis is sometimes challenging2. In these cases, quantitative HBsAg as an additional serological parameter can be used to discern different phases of chronic HBV infection, e.g. ENI versus ENH3,4. However, additional markers are needed to improve our understanding of HBV pathogenesis. Due to the importance of immune responses in controlling the virus and finally resolving HBV infection, cytokines and chemokines might be a promising approach to further optimize the prediction of the natural course of chronic HBV infection. In patients infected with hepatitis C virus (HCV), several studies could show the importance of CXCL10 or also known as IP-10 (IFN-γ-inducible protein of 10 kD) in prediction of response in patients undergoing combination therapy of pegylated interferon α (PEG-IFN) and ribavirin5 or spontaneous clearance of acute HCV infection6. CXCL10 may also play an important role in HBV infection, for example, CXCL10 is up-regulated in the liver during acute HBV infection in chimpanzees7. In HBV/HCV co-infected patients, dominance of HCV was associated with higher CXCL10 and lower quantitative HBsAg levels8,9. In HBV patients undergoing therapy with PEG-IFN or nucleos(t)ide analogues (NA), high baseline CXCL10 level were associated with HBsAg decline during therapy9-11.

In this study, we assessed 14 soluble immune markers (SIM) including CXCL10 in different phases of chronic HBV infection in a large European cohort to identify additional immune marker, which should help to differentiate the phases of chronic HBV infection.

Material and Methods

Patient population. Three hundred thirty-three European patients with persistent HBV infection, not undergoing antiviral therapy, were included in this cross-sectional study (Table 1).

Patients were recruited at the outpatient clinic of Hannover Medical School, Germany. One hundred thirty-four patients were HBeAg positive and 199 were HBeAg negative. They included 190 males and 143 females with a median age of 32 years (min. 1, max. 69 yrs.). None of the included individuals were co-infected with hepatitis δ virus (HDV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV). Further exclusion criteria were end-stage liver insufficiency, alcoholism, autoimmune disorders, immunosuppressive treatment and malignancies. Patients were divided according to their phase of chronic HBV infection or hepatitis defined according to EASL2:

- HBeAg-positive chronic infection (EPI, n = 45)
- HBeAg-positive chronic hepatitis (EPH, n = 89),
- HBeAg-negative chronic infection (ENI, n = 88)
- HBeAg-negative chronic hepatitis (ENH, n = 63)
- HBeAg-negative chronic infection, high replicative (HBV DNA > 20,000, ALT normal) (ENI-HR, n = 48).

The high replicative status in HBeAg negative chronic infection (ENI-HR) was assessed, when DNA levels were between 2,000 and 20,000 IU/mL in at least two consecutive time-points with ALT levels less or equal the upper limit of norm (ULN). For a 2nd analysis a subpopulation of patients with chronic HBV infection (n = 39 out of 333) and patients with acute HBV (n = 10) infection or patients with suppressed HBV-DNA under nucleos(t)ide analogues (NA) therapy were included.

Serum HBsAg quantification. Abbott ARCHITECT assay (Abbott Diagnostics, Abbott Park, IL) was used to quantify serum HBsAg levels.

The dynamic range of the test is 0.05–250 IU/mL. Samples were diluted 1:100 in horse serum and if HBsAg levels were >250 IU/mL, samples were retested at a dilution of 1:500 and 1:1,000, respectively. Samples with HBsAg levels <0.05 IU/mL were retested without prior dilution. Results are given in IU/mL.

HBV-DNA measurement. Serum HBV-DNA was quantified by usage of COBAS AmpliPrep/COBAS TaqMan (Roche Diagnostics, Mannheim, Germany) and TaqMan Universal Master Mix (Applied Biosystems, Foster City, CA) with detection limits of 12 IU/mL and 50 IU/mL, respectively. HBV-DNA results are expressed in IU/mL.

HBV genotyping. HBV genotyping was assessed in 254 patients. DNA was extracted from 200µL of serum using High Pure Viral Nucleic Acid Kit (Roche Diagnostics, Mannheim, Germany) according to the manufacturer’s protocol. HBV genotype was determined by a modified RFLP PCR assay with amplified HBV-DNA by use of a nested PCR as previously described11. The sequences abstracted were matched with the National Center for Biotechnology Information GenBank and compared with described HBV-prototypes (Accession No. for: HBV-A Z72478; HBV-B D00329; HBV-C X01587; HBV-D V01460; HBV-E X75658; HBV-G AF160501). The HBV S sequence and related references sequences were aligned with CLC Main Workbench 6 (CLCBio, Aarhus, Denmark). Genetic distance was estimated also by use of CLC Main Workbench 6. Bootstrap resampling and reconstruction were carried out 1,000 times.

Quantification of soluble immune mediators (cytokines and chemokines). The concentrations of following SIM were measured in sera/plasma using the Luminesin-based multiplex technology. In all patients
Table 1. Baseline characteristics and factors univariately differentiating between patients in different phases of chronic HBV infection based on ANOVA (continuous variables) and Chi-Square analysis (discrete values). *In EPI group patients with ALT < 1.5ULN were accepted if no inflammation in liver biopsy was observed. In ENH group patients with ALT 1.0–1.5 ULN were accepted if significant inflammation (A1 > 2) in liver biopsy was observed.

|                   | EPI (n = 45) HBV-DNA > 10^4 IU/ml, ALT < ULN* | EPI (n = 89) HBV-DNA > 2,000 IU/ml, ALT ≥ 1.5ULN | ENI (n = 88) HBV-DNA < 2,000 IU/ml, ALT < ULN | ENI (n = 63) HBV-DNA ≥ 2,000 IU/ml, ALT ≥ 1.5ULN | ENI-HR (n = 40) HBV-DNA 2,000–20,000 IU/ml, ALT < ULN | ANOVA p-value or χ² |
|-------------------|-----------------------------------------------|-------------------------------------------------|-----------------------------------------------|-------------------------------------------------|-------------------------------------------------|---------------------|
| Age, yrs (median, min.-max) | 18 (1–49)                                    | 28 (7–68)                                       | 41 (12–69)                                    | 41 (22–67)                                       | 29 (14–63)                                       | <0.001              |
| Gender, n (M/F)     | 25/20                                        | 66/23                                          | 40/48                                         | 41/22                                           | 18/30                                           | <0.001              |
| HBV DNA log₁₀ IU/ml (median, 10–90% CI) | 8.07 (7.75, 9.25) | 8.04 (5.23, 8.98) | 2.29 (1.08, 3.11) | 5.56 (3.95, 8.01) | 3.83 (3.39, 4.22) | <0.001 |
| HbsAg log₁₀ IU/ml (median, 10–90% CI)   | 4.96 (4.34, 5.36) | 4.31 (3.46, 5.16) | 3.11 (0.87, 4.11) | 3.91 (2.77, 4.39) | 3.79 (3.05, 4.36) | <0.001 |
| ALT (ULN) (median, 10–90% CI)          | 2.69 (1.59, 10.80) | 0.65 (0.42, 0.92) | 2.35 (1.39, 11.69) | 0.67 (0.43, 0.89) | 0.001                                          |
| Bilirubin (ULN)      | 0.41 (0.19, 0.82) | 0.53 (0.24, 1.34) | 0.47 (0.29, 0.82) | 0.73 (0.29, 1.20) | 0.53 (0.28, 1.19) | 0.038   |
| Platelets, 10^9/µL (median, 10–90% CI) | 242 (183, 335) | 198 (127, 292) | 220 (152, 298) | 189 (103, 251) | 224 (168, 286) | <0.001 |
| cirrhosis n (%)      | 1 (2.2)                                      | 12 (13.4)                                      | 10 (11.3)                                     | 6 (9.5)                                         | 2 (4.2)                                         | 0.301   |

**In-vitro Peptide stimulation and intracellular staining (ICS).** To study the effect of IL-12 on T cells, thawed PBMCs from two EPI patients were stimulated for 10 days with 2.5 µg/ml HBV core overlapping peptides (OLPs) (Genotype D, Proimmune, UK) in presence of 10 ng/ml rhIL-12 (Milleniy Biotech). 41 HBV core OLPs were divided into 2 pools; HBV core peptides #1 including 20 peptides and HBV core peptides #2 including 21 peptides. Cultures were supplemented with 5 U/ml rhIL-2 (Invitrogen Life Technologies) at days 4 and 8. Cells were restimulated at day 10 with the same HBV core OLPs and rhIL-12 for 6 hours. 2 µg/ml Brefeldin A (Sigma-Aldrich) was added after 1 hour of restimulation. For cell surface staining, PBMCs were stained with CD3 (Biolegend), CD14 (BD Bioscience), CD19 (BD Bioscience), CD4 (BD Bioscience) and CD8 (Biolegend). Dead cells were excluded using the Aqua cell stain kit (Life technologies). After fixation and permeabilization of PBMCs with Foxp3/Transcription Factor Staining Buffer Set (Ebioscience/Thermofisher), they were stained for IFN-γ (BD Bioscience) and TNF (Biolegend) for 30 min. Samples were acquired using BD LSR Fortessa (BD Biosciences) and data were analysed in FlowJo version 9.9.4 (Treestar).

**Statistical analyses.** Statistical analyses were performed by using SPSS software version 21 (SPSS Inc., Chicago, IL). P-values < 0.05 were considered as statistically significant. If not otherwise noted, all values mentioned are the median and 10–90% confidence interval. Correlation was tested with the Spearman correlation test.

A chi-square test was calculated for the comparison of discrete variables. For univariate analyses, we applied the Mann–Whitney U test for continuous data. Multivariate analyses were performed with the Kruskal–Wallis ANOVA. Multivariate logistic regression analyses were performed by using the likelihood ratio test for backward selection.
To prevent bias from different types of samples (sera/plasma), median values were calculated at first. The quotient of median in plasma results divided by median in serum results was multiplied by each serum result for each cytokine. SIM concentrations were logarithmized (log10) in order to utilize parametric mathematics.

For analysis of cytokine patterns an outlier analysis was performed. For evaluation we used a 50-fold median threshold and a 1/50th median threshold in each group. All parameters, which were not located in this range, were deleted for the following analysis.

**Ethical approval.** This retrospective study was conducted in accordance with the guidelines of the Declaration of Helsinki, the principles of Good Clinical Practice and according to standards of the local ethics committee. All patients provided informed consent for the analysis of parameters assessed in stored blood samples taken during routine diagnostics. Data were analyzed anonymously. The local ethical committee of Hannover Medical School approved the retrospective, anonymous retesting of patient samples and the anonymous analysis of patient data.

**Results**

In this study 333 HBsAg positive patients were grouped in four consecutive phases of chronic HBV infection (EPI, EP, ENI, ENH) and in the HBeAg-negative chronic infection with high replication (ENI-HR) (Table 1). HBeAg-positive patients (ENI and EP) were significantly younger than patients with HBeAg-negative chronic HBV infection or hepatitis (EPI: 18.8 ± 9.9, EP: 32.4 ± 16.0, ENI: 40.9 ± 14.6, ENH: 40.8 ± 11.2, p < 0.001, [years]). The proportion of females in ENI and ENI-HR was higher than in the EP and ENH phases. HBV genotype distribution and prevalence of liver cirrhosis was similar between the different phases of chronic HBV-infection (Table 1).

Baseline characteristics of patients in the 2nd subpopulation with concentrations of 52 SIM are shown in Table S1.

**Distribution of HBsAg levels.** Serum HBsAg levels differed between the different phases in chronic hepatitis B patients (Fig. 1). Levels were highest in EPI patients (4.96 log10 IU/mL). In the EP group the median HBsAg titer was 4.31 log10 IU/mL, whereas in ENI the lowest median HBsAg result was observed (3.11 log10 IU/mL) (Fig. 1). Quantitative HBsAg (qHBsAg) data of the other two HBeAg negative phases (ENI and ENI-HR) compared with the results of EPH patients were more than 4.5- and 6.5-fold lower, respectively (3.91 log10 IU/mL and 3.79 log10 IU/mL) (Fig. 1). Interestingly, there was no significant difference in qHBsAg results between ENH and ENI-HR (p = 0.754).

**Distribution of cytokine and chemokine (soluble inflammatory marker) levels.** Univariate ANOVA revealed several serological, biochemical and immunological parameters, which differed between the groups (Table 2; Fig. 2A).

For a better visualization a heat map showing expression patterns of SIM were created (Fig. 2B and Supplementary Fig. S1).

We have also tested the correlation between 14 cytokine levels and ALT and HBV DNA levels. We identified significant correlation between cytokine levels and ALT, especially in EPH and ENH, but weak correlation between expression levels and HBV DNA levels (Fig. 3A). CXCL10 concentrations showed the strongest correlation to ALT titers in EPH (r = 0.53, p < 0.001) and ENH patients (r = 0.43, p < 0.001) (Fig. 3B).

In line with this data, CXCL10 showed the strongest signal among all SIM considering differentiation of HBV phases.

The highest CXCL10 concentrations were observed in the EPH and ENH patients with a median of 2.39 ± 0.36 log10 pg/mL and 2.38 ± 0.36 log10 pg/mL, respectively. Significantly lower CXCL10 concentrations were documented in patients without hepatitis in the EPI- (2.04 ± 0.36 log10 pg/mL; p < 0.001), ENI- (1.98 ± 0.32 log10 pg/mL; p < 0.001) or ENI-HR phase (2.08 ± 0.19 log10 pg/mL; p < 0.001) (Fig. 4A).

Among difficult-to-distinguish HBeAg negative individuals (ENI, ENI-HR) CXCL10, CCL4 (MIP-1β), IL-17, TGF-β1, -β2 and -β3, TNF-α, IL-12 (IL-12p70) and IL-16 differed significantly (Table 3) between these groups. CXCL10 concentrations were able to dissect ENH from ENI-HR and ENI from ENH. ENI patients had lower IL-12 and CCL4 levels (−0.73 ± 0.84 log10 pg/mL and 1.18 ± 0.28 log10 pg/mL) compared to ENH patients (−0.19 ± 0.90 log10 pg/mL and 1.38 ± 0.35 log10 pg/mL, Mann-Whitney U test; p < 0.001, respectively).

Interestingly, only TGF-β2 and IL-17 were useful to differentiate between ENI and ENI-HR.

In ENI individuals, median concentrations of TGF-β2 were 3.67 ± 0.14 log10 pg/mL and thus higher than in patients classified to ENI-HR (3.57 ± 0.13 log10 pg/mL; Mann-Whitney U test; p = 0.001). IL-17 levels were 0.03 ± 0.43 log10 pg/mL in ENI patients and −0.22 ± 0.42 log10 pg/mL in ENI-HR patients; Mann-Whitney U test; (p = 0.040) (Fig. 4B). Performing a multivariate analysis only TGF-β remained an independent parameter for the differentiation of ENI- and ENI-HR patients (p < 0.001).

For an easier understanding, we restricted further analyzes to TGF-β2 when referring to TGF-β, based on the observed correlation between TGF-β2 and TGF-β3 (r = 0.79; p < 0.001) and between TGF-β3 and TGF-β2 (r = 0.83; p < 0.001) (Figs S2a and S2b).

In a 2nd smaller cohort of chronic HBV patients with available data for 52 SIM, CXCL10 and TGF-β data were confirmed. In addition, sCD40L, PDGF-BB and RANTES differed between various phases of chronic HBV infection (Table S2).

SIM concentration patterns of patients with four phases of chronic HBV infection (EPI-HR not included) and SIM concentrations of acute hepatitis B patients, patients with HBV-DNA suppression and healthy individuals were shown in Table S1.
are visualized in Fig. S3. Of note, CXCL10 values were high in patients with acute hepatitis B and low in healthy controls and NA treated patients with HBV suppression.

Cytokines in patients with HBeAg seroconversion. For 10 HBeAg positive patients with no history of antiviral therapy \((n = 5 \text{ EPH and } n = 5 \text{ EPI})\) a second time point after seroconversion to anti-HBeAg was available (Table S3). The mean range between both time points was 4 years and 8 months (range 12 months–84 months).

Comparing only those HBeAg seroconverters, who were considered as part of the EPI population before seroconversion with the other EPI patients with unknown outcome, higher IL-12 levels \((-0.13 \pm 0.54 \log_{10}\text{pg/mL vs. } -0.86 \pm 1.05 \log_{10}\text{pg/mL}; p = 0.029)\) were documented (Fig. S4A). In addition, the seroconverters were younger than the rest of the EPI patients \((6 \pm 4 \text{ years vs. } 20 \pm 10 \text{ years}; p = 0.008)\). After HBV seroconversion the values for TNF-α and ALT were lower than before in those patients \((-0.31 \pm 0.27 \log_{10}\text{pg/mL vs. } 0.34 \pm 0.38 \log_{10}\text{pg/mL}; p = 0.005 \text{ and } 0.62 \pm 0.13 \text{ ULN vs. } 0.98 \pm 0.19 \text{ ULN; p = 0.044})\).

Analyses of HBeAg seroconverters formerly grouped to EPH phase showed no difference in cytokine values, HBsAg titers or levels of transaminases compared to patients in the EPH phase with no documented HBeAg seroconversion. When comparing HBeAg seroconverters classified as EPH patients before and after seroconversion, only IL-17 levels \((0.47 \pm 0.19 \log_{10}\text{pg/mL vs. } -0.28 \pm 0.40 \log_{10}\text{pg/mL}; p = 0.032)\), showed significant differences.

Effect of IL-12 on T cell responses. To confirm the previously published data that IL-12 has an impact of HBV-specific T cell responses\(^1\), we have investigated the \textit{in-vitro} effect of IL-12 on HBV core peptide stimulated PBMCs isolated from two young HBeAg positive patients with high HBsAg levels. After 10 days \textit{in-vitro} HBV core peptide stimulation, CD4\(^+\), as well as CD8\(^+\) T cells, showed higher IFN-γ/TNF production assessed by an intracellular cytokine assay after IL-12 plus HBV core peptide re-stimulation compared with peptide stimulation only (Fig. S4B).

Table 2. Evaluation of significant differences between different phases of chronic HBV patients by using Kruskal-Wallis ANOVA \((A = \text{EPI vs. EPH}; B = \text{EPI vs. ENI}; C = \text{EPI vs. ENH}; D = \text{EPH vs. ENI-HR}; E = \text{EPH vs. ENI}; F = \text{EPH vs. ENH}; G = \text{EPH vs. ENI-HR}; H = \text{ENI vs. ENH}; I = \text{ENI vs. ENI-HR}; J = \text{ENH vs. ENI-HR})\).

| Analyte       | P value   | Q Value   | Group       |
|---------------|-----------|-----------|-------------|
| HBV DNA       | \(5.42 \times 10^{-110}\) | \(4.35 \times 10^{-114}\) | ABCDEFGHIJ  |
| HBsAg         | \(1.47 \times 10^{-128}\) | \(5.89 \times 10^{-15}\) | ABCDEFGHI   |
| CXCL10        | \(5.80 \times 10^{-19}\) | \(1.16 \times 10^{-17}\) | ACGFJ       |
| Age           | \(1.13 \times 10^{-17}\) | \(1.81 \times 10^{-17}\) | ABCDEFIJ    |
| ALT           | \(4.23 \times 10^{-11}\) | \(3.15 \times 10^{-11}\) | ACGFJ       |
| CCL4          | \(1.18 \times 10^{-8}\) | \(6.31 \times 10^{-9}\) | EGH         |
| IL-17         | \(3.92 \times 10^{-9}\) | \(1.97 \times 10^{-9}\) | EGH         |
| TGF-β         | \(3.93 \times 10^{-7}\) | \(1.86 \times 10^{-7}\) | DGI         |
| TNF-α         | \(7.85 \times 10^{-4}\) | \(2.86 \times 10^{-4}\) | CHI         |
| IL-12p70      | \(2.58 \times 10^{-3}\) | \(8.12 \times 10^{-4}\) | EH          |
| IL-16         | \(2.83 \times 10^{-3}\) | \(8.74 \times 10^{-4}\) | CFH         |
| IFN-γ         | \(9.99 \times 10^{-3}\) | \(2.82 \times 10^{-3}\) | CH          |

Figure 1. qHBsAg titers in chronic HBV. HBsAg titers in different phases of chronic HBV infection were quantified by using Abbott ARCHITECT assay (red: HBeAg positive, blue: HBeAg negative). Mann-Whitney U test was used for comparison of means.

**Table 2.** Evaluation of significant differences between different phases of chronic HBV patients by using Kruskal-Wallis ANOVA \((A = \text{EPI vs. EPH}; B = \text{EPI vs. ENI}; C = \text{EPI vs. ENH}; D = \text{EPH vs. ENI-HR}; E = \text{EPH vs. ENI}; F = \text{EPH vs. ENH}; G = \text{EPH vs. ENI-HR}; H = \text{ENI vs. ENH}; I = \text{ENI vs. ENI-HR}; J = \text{ENH vs. ENI-HR})\).
Discussion

The differentiation of the phases of chronic HBV infection is important to individualize the management of the patients. However, a single determination of HBV DNA, as well as disease activity markers, does not allow an immediate classification to one of the phases. Quantitative HBsAg (qHBsAg) titers may help to improve the differentiation between phases in HBV infection\cite{ref5, ref17}. Our results confirm data from previous studies that HBsAg
Figure 3. Correlation of SIM and ALT or HBV DNA. (A) Spearman rank correlation coefficients between SIM levels (rows) and ALT (left panel) or HBV DNA (right panel). Red indicates a significant positive correlation, whereas blue indicates a significant negative correlation. White color indicates non-significant (n.s.). (B) Spearman rank correlation between CXCL-10 and ALT in EPH (left) and ENH patients (right).

Figure 4. CXCL10, TGF-β and IL-17 titers in different phases of chronic HBV infection. (A) CXCL10 levels in HBeAg-positive and HBeAg-negative phases of chronic HBV infection (B) TGF-β and IL-17 levels in HBeAg-negative phases of chronic HBV infection. Mann-Whitney U test was used for comparison of means.
levels differ between the phases of chronic HBV infection. However, qHBsAg could not distinguish patients with ENH and patients with high replicative HBeAg negative infection (ENI-HR). Importantly, our study showed that soluble immune mediators could be a valuable additional tool to better characterize patients with chronic HBV infection including those with HBeAg negative infection.

Among 14 tested SIM, CXCL10 was the most significant SIM that helped to distinguish the different phases of chronic HBV infection. This was confirmed in a second smaller cohort. CXCL10 is known to be a mainly pro-inflammatory chemokine which has, among other functions, an impact in pathogenesis of chronic inflammatory in miscellaneous infectious diseases. CXCL10 may play a role in regulating activity for cell proliferation and induction of apoptosis. This is an explanation why CXCL10 concentrations are highest in phases of active hepatitis and in patients with acute hepatitis B and, thus, may have an impact as an immunological imprint in the prognosis of the disease. High CXCL10 levels may suggest stronger immune activation, which can lead to disease progression.

However, this may sometimes even be beneficial i.e. if these patients receive an additional treatment. Several studies could show that higher CXCL10 levels were associated with HBsAg decline and HBeAg loss in response to pegylated Interferon alfa therapy and in patients undergoing antiviral therapy with nucleos(t)ide analogues. In HCV/HBV co-infected patients higher CXCL10 levels in HCV dominant patients were associated with lower HBsAg concentrations compared with HBV dominant patients or HBV mono-infected patients. If HBV is controlled by immune responses, i.e. in inactive carriers (ENI), or in patients on NA therapy, CXCL10 levels are low. In fact, in that case, lower CXCL10 levels may indicate that patients may clear HBsAg later on. Thus, it is important to interpret the value of CXCL10 in the context of the different phases of HBV infection.

In the few patients analyzed longitudinally, CXCL10 was not significantly higher in patients who developed spontaneous HBeAg seroconversion compared with all HBeAg positive patients. This may suggest that CXCL10 alone is not sufficient in this situation and as discussed above, additional antiviral therapy may be important. But interestingly, patients in the EPI phase who could experience HBeAg seroconversion had significantly higher levels of IL-12 than patients in the EPI phase with unknown follow-up. The number of patients tested is small, but IL-12 was described to have an impact in restoring Th1 T cell functions. Exhausted CD8+ T cells, which are present in chronic HBV infection and in part responsible for the persistence of HBV could gain their functionality back by induction of IL-12. IL-12 is known to improve cytotoxicity, polyfunctionality and multispecificity of HBV-specific T cells. We could confirm the results shown by Schurich et al that IL-12 could enhance the in-vitro HBV-specific T cell responses in two young HBeAg positive EPI patients. Thus, concepts to improve T cell responses including IL-12 induction may be considered for future immune therapies for chronic hepatitis B.

Importantly, patients with subsequent seroconversion were younger compared with those patients with unknown outcome. The higher IL-12 level in these young seroconverters suggests the presence of immune responses and is in line with recent data challenging the concept of immune tolerance in young patients with HBeAg positive infection.

Another interesting result was the difference in transforming growth factor-beta (TGF-β) and IL-17 among HBeAg negative patients. ENI-HR patients had the lowest levels of TGF-β and IL-17. It has been shown that TGF-β is involved in the development of Th17 cells, which are the source of IL-17. TGF-β is known to improve cytotoxicity, polyfunctionality and multispecificity of HBV-specific T cells. We could confirm the results shown by Schurich et al. that IL-12 could enhance the in-vitro HBV-specific T cell responses in two young HBeAg positive EPI patients. Thus, concepts to improve T cell responses including IL-12 induction may be considered for future immune therapies for chronic hepatitis B.

The current study is one of the first larger cross-sectional studies with more than 300 patients presenting insights in different cytokine and chemokine levels in the different phases of chronic HBV infection. Limitations of this study were its retrospective design and in general a lack of follow-up data including clinical endpoints. The impact of the results was limited because this cross-sectional study provided no solid evidence to explain how the SIM influence disease progression and vice versa or if viral factors such as precore or BCP mutations influence the results. Prospective longitudinal studies following patients that switch the phases of chronic HBV infection are warranted to address this important question. In addition, the study in more than 300 patients was limited to only

| Table 3. Significant differences of SIM concentrations in HBeAg negative phases of chronic HBV; Kruskal-Wallis ANOVA. *log10 pg/mL (median, 10–90% CI). |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| SIM             | ENI (n = 88)    | ENH (n = 63)    | HRC (n = 48)    | ANOVA p-value   |
| CXCL10*         | 1.98 (1.68, 2.40) | 2.38 (2.02, 2.87) | 2.08 (1.82, 2.32) | <0.001          |
| CCL4*           | 1.18 (0.94, 1.55) | 1.38 (1.08, 1.93) | 1.22 (0.97, 1.50) | <0.001          |
| IL-12*          | 0.03 (−0.49, 0.48) | 0.23 (−0.15, 0.72) | −0.22 (−0.63, 0.34) | <0.001          |
| TGF-α2          | 4.33 (4.01, 4.74) | 4.46 (4.20, 5.08) | 4.33 (4.03, 4.59) | 0.002           |
| TGF-β31          | 3.67 (3.55, 3.77) | 3.68 (3.60, 3.82) | 3.57 (3.37, 3.72) | <0.001          |
| TGF-32          | 3.11 (2.77, 3.41) | 3.14 (2.94, 3.49) | 3.12 (2.59, 3.29) | 0.007           |
| TGF-33          | 0.02 (−0.36, 0.60) | 0.34 (−0.27, 1.64) | 0.00 (−0.31, 0.76) | <0.001          |
| IL-12*          | −0.73 (−2.00, 0.23) | −0.19 (−1.91, 0.84) | −0.52 (−2.00, 0.24) | 0.002           |
| IL-16*          | 1.67 (1.32, 2.28) | 1.88 (1.32, 2.87) | 1.71 (1.26, 2.13) | 0.001           |
a small subset of SIM and we could not define thresholds for single SIM that could be used for clinical practice. Non-specific reasons for different SIM level cannot be excluded.

However, the results confirm that CXCL10 may have an important role in chronic HBV infection. In addition, IL-17 may be an interesting marker to predict HBeAg seroconversion in young patients with HBeAg positive infection and TGF-3/IL-17 could be helpful to further characterize HBeAg negative patients. Additional studies should investigate the role of immune marker in larger cohorts of patients with HBV infection.

Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

All data generated or analysed during this study are included in this published article (and its Supplementary Information files).

References
1. Schweitzer, A., Horn, J., Nikolajczyk, R. T., Krause, G. & Ott, J. J. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. *Lancet Lond. Engl.* https://doi.org/10.1016/S0140-6736(15)61412-X (2015).
2. Lampertico, P. et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. *J. Hepatol.* 67, 370–398 (2017).
3. Papatheodoridis, G. V., Manolakopoulos, S., Liaw, Y.-F. & Lok, A. Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT. A systematic review. *J. Hepatol.* 57, 196–202 (2012).
4. Brunetto, M. R. et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. *Gastroenterology* 139, 483–490 (2010).
5. Cornberg, M. et al. The role of quantitative hepatitis B surface antigen revisited. *J. Hepatol.* 66, 398–411 (2017).
6. Lagging, M. et al. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. *Hepatology* 44, 1617–1625 (2006).
7. Reinhardt, S. et al. Serum level of IP-10 increases predictive value of IL28 polymorphisms for spontaneous clearance of acute HCV infection. *Gastroenterology* 142, 78–85.e2 (2012).
8. Cornberg, M. & Wiegand, S. B. ImpOrtance of IP-10 in hepatitis B. *Antivir. Ther.* 21, 93–96 (2016).
9. Wieland, S., Thimme, R., Purcell, R. H. & Chisari, F. V. Genomic analysis of the host response to hepatitis B virus infection. *Proc. Natl. Acad. Sci. USA* 101, 6669–6674 (2004).
10. Wiegand, S. B. et al. Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-γ-induced protein 10 levels in HBV/HCV-coinfected patients. *Clin. Microbiol. Infect.* 21, 710.e1–710.e9 (2015).
11. Sonneveld, M. J., Arends, P., Boonstra, A., Hansen, B. E. & Janssen, H. L. A. Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B. *J. Hepatol.* 58, 889–903 (2013).
12. Wang, Y. et al. Predictive value of interferon-gamma inducible protein 10 KD for hepatitis B e antigen clearance and hepatitis B surface antigen decline during pegylated interferon alpha therapy in chronic hepatitis B patients. *Antiviral Res.* 103, 51–59 (2014).
13. Jaroszewicz, J. et al. Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues. *Antivir. Ther.* 16, 915–924 (2011).
14. Toan, N. L. et al. Hepatitis B virus genotype and genotype mixtures on the course of liver disease in Vietnam. *Hepatol. Baltim. Md* 43, 1375–1384 (2006).
15. Schurrich, A. et al. The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cells. *PLoS Pathog.* 9, e1003208 (2013).
16. Martinot-Peignoux, M. et al. Prediction of disease reactivation in asymptomatic hepatitis B patients undergoing nucleoside/ nucleotide analogues. *Antivir. Ther.* 78–85.e2 (2012).
17. Nguyen, T. et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. *J. Hepatol.* 60, 62–68 (2014).
18. Schurrich, A. et al. The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cells. *PLoS Pathog.* 9, e1003208 (2013).
19. Wang, Y. et al. CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. *Cytokine Growth Factor Rev.* 22, 121–130 (2011).
20. Wang, Y. et al. Predictive Value of Serum IFN-γ Inducible Protein-10 and IFN-γ/IL-4 Ratio for Liver Fibrosis Progression in CHB Patients. *Sci. Rep.* 7 (2017).
21. Zhan, K. et al. IP-10 Expression in Patients with Chronic HBV Infection and Its Ability to Predict the Decrease in HBsAg Levels after Treatment with Entecavir. *Mol. Cells* 40, 418 (2017).
22. Wong, G. L.-H. et al. Serum interferon-inducible protein 10 levels predict hepatitis B s antigen seroclearance in patients with chronic hepatitis B. *Aliment. Pharmacol. Ther.* 43, 145–153 (2016).
23. Kennedy, P. T. F. et al. Preserved T-Cell Function in Children and Young Adults With Immune-Tolerant Chronic Hepatitis B. *Gastroenterology* 143, 637–645 (2012).
24. Korn, T., Bettelli, E., Oukka, M. & Kuchroo, V. K. IL-17 and Th17 Cells. *Annu. Rev. Immunol.* 27, 485–517 (2009).
25. Dubuiron, O. et al. Receiver-operating characteristic and pathogenetic effectors in HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapy. *J. Hepatol.* 60, 62–68 (2014).
26. Toan, N. L. et al. Impact of the hepatitis B virus genotype and genotype mixtures on the course of liver disease in Vietnam. *Hepatol. Baltim. Md* 43, 1375–1384 (2006).
27. Schurrich, A. et al. The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cells. *PLoS Pathog.* 9, e1003208 (2013).
28. Martinot-Peignoux, M. et al. Prediction of disease reactivation in asymptomatic hepatitis B patients undergoing nucleoside/ nucleotide analogues. *Antivir. Ther.* 78–85.e2 (2012).
29. Nguyen, T. et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. *J. Hepatol.* 60, 62–68 (2014).
30. Liu, M. et al. CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. *Cytokine Growth Factor Rev.* 22, 121–130 (2011).
31. Wang, Y. et al. Predictive Value of Serum IFN-γ Inducible Protein-10 and IFN-γ/IL-4 Ratio for Liver Fibrosis Progression in CHB Patients. *Sci. Rep.* 7 (2017).
32. Zhan, K. et al. IP-10 Expression in Patients with Chronic HBV Infection and Its Ability to Predict the Decrease in HBsAg Levels after Treatment with Entecavir. *Mol. Cells* 40, 418 (2017).
33. Wong, G. L.-H. et al. Serum interferon-inducible protein 10 levels predict hepatitis B s antigen seroclearance in patients with chronic hepatitis B. *Aliment. Pharmacol. Ther.* 43, 145–153 (2016).
34. Kennedy, P. T. F. et al. Preserved T-Cell Function in Children and Young Adults With Immune-Tolerant Chronic Hepatitis B. *Gastroenterology* 143, 637–645 (2012).
35. Korn, T., Bettelli, E., Oukka, M. & Kuchroo, V. K. IL-17 and Th17 Cells. *Annu. Rev. Immunol.* 27, 485–517 (2009).
36. Bettelli, E. et al. Reciprocal developmental pathways for the generation of pathogenic effector T\(_{h}\)17 and regulatory T cells. *Nature* 443, 235–238 (2006).
37. Wang, Y. et al. Increased Th17 cells and interleukin-17 contribute to immune activation and disease aggravation in patients with chronic hepatitis B virus infection. *Immunol. Lett.* 149, 41–49 (2013).
38. Sun, H. Q. et al. Increased Th17 cells contribute to disease progression in patients with HBV-associated liver cirrhosis. *J. Viral Hepat.* 19, 396–403 (2012).
39. Paquissi, F. C. Immunity and Fibrogenesis: The Role of Th17/IL-17 Axis in HBV and HCV-Induced Chronic Hepatitis and Progression to Cirrhosis. *Front. Immunol.* 8 (2017).

Acknowledgements
We like to thank Janina Kirschner, Birgit Bremer, Regina Raupach, Kerstin Daemen and Jana Keil for excellent technical support. This study was supported by the German Center for Infection Research (DZIF, TTU 05.702 and TTU 05.806, TTU-IICH 07.801). We thank all the contributors of the study and all patients recruited.
Author Contributions
S.B.W., J.J., H.W., M.P.M., M.C., C.J.X. and Y.L.: conception, design, interpretation, and manuscript writing; S.B.W., C.F.: measurement of soluble inflammatory marker (SIM). E.A. and A.R.M.K. performed the T cell assays. S.B.W., B.B., A.W., J.J., T.L., H.W., C.F., M.C., C.J.X. and Y.L.: data analysis, and interpretation of data; Final approval of manuscript (all authors).

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-50729-5.

Competing Interests: J.J. has received compensation as a member of the scientific advisory board of Abbvie, Bristol-Myers Squib, Gilead Sciences, MSD Sharp & Dohme/Merck and Roche. He also hold lectures for Abbvie, Bristol-Myers Squib, Dia Sorin, Gilead Sciences, Grifols, MSD Sharp & Dohme/Merck, Roche, Woerwag and received lecture fees. M.P.M. has been funded by Roche, Bristol Myers Squibb, Gilead. He has received honoraria for consulting/holding lectures for Roche, Bristol Myers Squibb, Medgenics, Enyo Pharma, Curevac. H.W. has received honoraria for consulting/speaking from BMS, Gilead, Janssen, Roche Diagnostics, Abbott, Roche. M.C.s work has been funded by Roche Pharma. He has received compensation as a member of the scientific advisory board of Abbvie Deutschland GmbH, Bristol-Myers Squibb, Biogen Idec, Gilead Sciences, Janssen-Cilag, MSD Sharp & Dohme/Merck, Roche Diagnostics Roche Pharma. He also hold lectures for Falk Foundation e V. and received lecture fees. S.B.W., C.F., E.A., A.R.M.K., B.B., A.W., C.J.X., Y.L. and T.L. declare no potential conflict of interest.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019